News Novo Nordisk's dropping share price spells the end for CEO Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.
News Novo makes fresh obesity play with $2.2bn Septerna deal A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.
News Novo Nordisk builds case for Norditropin successor Novo Nordisk's long-acting growth hormone Sogroya works as well as Norditropin in a trio of paediatric growth disorders, with far fewer injections.
News More data backs Zepbound over Wegovy for weight loss Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.
News FDA decision on oral Wegovy coming in Q4 Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form.
